ネクセラファーマの株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2023/05/08 | 2,860 | 2,897 | 2,828 | 2,858 | +20 | +0.7% | 1,416,500 |
2023/05/02 | 2,757 | 2,838 | 2,748 | 2,838 | +98 | +3.6% | 1,710,300 |
2023/05/01 | 2,680 | 2,760 | 2,675 | 2,740 | +69 | +2.6% | 1,235,900 |
2023/04/28 | 2,625 | 2,675 | 2,598 | 2,671 | +68 | +2.6% | 1,305,400 |
2023/04/27 | 2,656 | 2,673 | 2,556 | 2,603 | -67 | -2.5% | 8,469,000 |
2023/04/26 | 2,725 | 2,734 | 2,658 | 2,670 | -41 | -1.5% | 1,492,000 |
2023/04/25 | 2,675 | 2,715 | 2,663 | 2,711 | +36 | +1.3% | 1,277,000 |
2023/04/24 | 2,676 | 2,698 | 2,666 | 2,675 | +16 | +0.6% | 1,132,100 |
2023/04/21 | 2,654 | 2,674 | 2,627 | 2,659 | +25 | +0.9% | 846,800 |
2023/04/20 | 2,620 | 2,670 | 2,609 | 2,634 | +17 | +0.6% | 1,030,800 |
2023/04/19 | 2,596 | 2,627 | 2,574 | 2,617 | +20 | +0.8% | 655,000 |
2023/04/18 | 2,599 | 2,627 | 2,576 | 2,597 | -9 | -0.3% | 976,100 |
2023/04/17 | 2,639 | 2,659 | 2,599 | 2,606 | -44 | -1.7% | 812,700 |
2023/04/14 | 2,624 | 2,670 | 2,616 | 2,650 | +1 | ±0% | 1,132,300 |
2023/04/13 | 2,589 | 2,679 | 2,580 | 2,649 | +66 | +2.6% | 1,620,000 |
2023/04/12 | 2,532 | 2,593 | 2,523 | 2,583 | +51 | +2% | 1,038,400 |
2023/04/11 | 2,573 | 2,579 | 2,515 | 2,532 | -11 | -0.4% | 1,439,200 |
2023/04/10 | 2,451 | 2,552 | 2,449 | 2,543 | +121 | +5% | 2,156,900 |
2023/04/07 | 2,428 | 2,465 | 2,387 | 2,422 | +21 | +0.9% | 730,100 |
2023/04/06 | 2,350 | 2,408 | 2,350 | 2,401 | +40 | +1.7% | 795,000 |
2023/04/05 | 2,400 | 2,401 | 2,357 | 2,361 | -44 | -1.8% | 689,600 |
2023/04/04 | 2,405 | 2,479 | 2,400 | 2,405 | +50 | +2.1% | 1,547,500 |
2023/04/03 | 2,310 | 2,441 | 2,307 | 2,355 | +88 | +3.9% | 1,726,000 |
2023/03/31 | 2,259 | 2,283 | 2,242 | 2,267 | +17 | +0.8% | 459,700 |
2023/03/30 | 2,253 | 2,292 | 2,241 | 2,250 | +23 | +1% | 709,900 |
2023/03/29 | 2,213 | 2,247 | 2,202 | 2,227 | +11 | +0.5% | 672,700 |
2023/03/28 | 2,173 | 2,230 | 2,130 | 2,216 | +75 | +3.5% | 958,700 |
2023/03/27 | 2,150 | 2,150 | 2,105 | 2,141 | -26 | -1.2% | 909,700 |
2023/03/24 | 2,182 | 2,185 | 2,148 | 2,167 | -15 | -0.7% | 679,600 |
2023/03/23 | 2,183 | 2,186 | 2,137 | 2,182 | -41 | -1.8% | 1,502,700 |
2023/03/22 | 2,269 | 2,272 | 2,196 | 2,223 | -14 | -0.6% | 1,575,600 |
2023/03/20 | 2,395 | 2,402 | 2,236 | 2,237 | -175 | -7.3% | 1,822,300 |
2023/03/17 | 2,420 | 2,445 | 2,376 | 2,412 | +11 | +0.5% | 747,200 |
2023/03/16 | 2,420 | 2,440 | 2,356 | 2,401 | -33 | -1.4% | 1,209,100 |
2023/03/15 | 2,441 | 2,453 | 2,377 | 2,434 | +43 | +1.8% | 1,493,000 |
2023/03/14 | 2,380 | 2,437 | 2,374 | 2,391 | -25 | -1% | 1,263,700 |
2023/03/13 | 2,410 | 2,441 | 2,362 | 2,416 | -44 | -1.8% | 1,033,600 |
2023/03/10 | 2,499 | 2,568 | 2,427 | 2,460 | -3 | -0.1% | 2,477,000 |
2023/03/09 | 2,417 | 2,469 | 2,404 | 2,463 | +126 | +5.4% | 3,743,100 |
2023/03/08 | 2,288 | 2,352 | 2,270 | 2,337 | +34 | +1.5% | 843,300 |
2023/03/07 | 2,310 | 2,345 | 2,292 | 2,303 | -19 | -0.8% | 541,800 |
2023/03/06 | 2,360 | 2,363 | 2,315 | 2,322 | -6 | -0.3% | 692,000 |
2023/03/03 | 2,240 | 2,375 | 2,240 | 2,328 | +102 | +4.6% | 1,740,200 |
2023/03/02 | 2,180 | 2,235 | 2,158 | 2,226 | +78 | +3.6% | 847,900 |
2023/03/01 | 2,207 | 2,223 | 2,136 | 2,148 | -58 | -2.6% | 1,000,100 |
2023/02/28 | 2,261 | 2,261 | 2,184 | 2,206 | -5 | -0.2% | 1,141,600 |
2023/02/27 | 2,309 | 2,309 | 2,199 | 2,211 | -137 | -5.8% | 1,940,200 |
2023/02/24 | 2,368 | 2,389 | 2,337 | 2,348 | -23 | -1% | 714,400 |
2023/02/22 | 2,421 | 2,421 | 2,360 | 2,371 | -73 | -3% | 1,069,100 |
2023/02/21 | 2,445 | 2,492 | 2,411 | 2,444 | +10 | +0.4% | 750,100 |
351~
400
件表示中 / 4944件
類似銘柄と比較する
現在ご覧いただいている「ネクセラファーマ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
ネクセラファーマ | 125,100円 | +197.7% | - | 0.00% | 51.12倍 | 1.63倍 |
|
創薬ベンチャー老舗。買収で成長。英国の創薬事業に日本が柱の後期治験・製造販売事業加わる |
ゼリア新薬 | 233,800円 | +9.6% | +17.5% | 1.97% | 13.21倍 | 1.29倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
鳥居薬 | 393,500円 | +11.1% | +20.6% | 3.05% | 23.05倍 | 0.92倍 |
|
JT傘下。柱の抗HIV薬販売権喪失後、自社製品の腎・透析、アレルゲン等の開発強化 |
杏林製薬 | 153,100円 | +3.2% | +4.5% | 3.40% | 17.59倍 | 0.67倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
栄研化 | 246,000円 | +7.6% | +57.5% | 2.15% | 19.02倍 | 1.87倍 |
|
臨床検査薬大手。便潜血検査試薬(FIT)はシェア7割。尿検査(ウロ)、遺伝子検査も育成 |
市場注目の銘柄
チャート関連のコラム